BioPorto Diagnostics, Thermo Fisher, Abbott diagnostic news
BioPorto announced agreements with two of the four companies with objections to the company's European Patent No. EP1831699, which covers a method of diagnosing renal disorders by applying a cutoff when measuring the concentration of the lipocalin ( LCN2; NGAL) biomarker. BioPorto reached a settlement with Thermo Fisher's Phadia AB subsidiary regarding Phadia's European Patent No. EP0756708. BioPorto will receive a worldwide license to Phadia's patents in the NGAL area. BioPorto also entered a non-exclusive agreement with Abbott to cross-license the companies' NGAL biomarker IP rights. The terms include upfront fees and royalties on sales for both parties. BioPorto declined to disclose financial terms, and Phadia and Abbott could not be reached. ...